Lorne 2012: The war on superbugs
16 February, 2012 by Fiona WylieLorne Infection & Immunity: Resistance to antibiotics is an increasingly serious threat to human health worldwide. Now, a new Wellcome Trust-funded partnership with scientists in Queensland is fighting back.
Heavy hitters in business development arriving
16 February, 2012 by AusBiotechThe biotech industry’s heavy hitters in business development are about to gather in Queensland for the annual dedicated forum for business development professionals.
Phosphagenics' redesigned pain patch shows improved results
16 February, 2012 by Dylan Bushell-EmblingA trial of Phosphagenics' (ASX:POH) new TPM/oxycodone patch design proves that the redesign improves drug delivery by 4.5 times the original prototype version.
William Ardrey to face fraud charges in WA
15 February, 2012 by Tim DeanFormer CEO of Avantogen, Dr William Ardrey, is to appear in Perth Magistrates Court this Friday on 19 counts of fraud.
Prima BioMed files for NASDAQ listing
14 February, 2012 by Dylan Bushell-EmblingSydney-based Prima BioMed (ASX:PRR) has filed a registration for a dual-listing on the NASDAQ exchange, a move first announced in 2010.
AusBiotech supporting industry employment
14 February, 2012 by AusBiotechAusBiotech has relaunched the employment section on its high-traffic website, giving members the opportunity to list vacancies free and qualified industry professionals access to the latest list of industry jobs.
LBT royalty deal lower than hoped
13 February, 2012 by Dylan Bushell-EmblingLab technology company LBT Innovations (ASX:LBT) has negotiated a less-than-hoped-for minimum royalty deal with licensee bioMérieux worth US$600,000 per year.
BioDiem licenses vaccine tech to China's BCHT
13 February, 2012 by Dylan Bushell-EmblingMelbourne biotech BioDiem (ASX:BDM) has awarded Changchun BCHT an exclusive license for the China private sector market covering its influenza vaccine technology.
Bioniche reports loss, focuses on animal health
10 February, 2012 by Dylan Bushell-EmblingDual-listed biopharma Bioniche (ASX:BNC) has posted a Q2 loss of $4m, and shareholders have been warned the company may have inadequate cash reserves for the next 12 months.
Trial shows Patrys melanoma antibody safe
10 February, 2012 by Dylan Bushell-EmblingMelbourne's Patrys Limited (ASX:PAB) has successfully concluded a safety and tolerability trial for its lead antibody, PAT-SM6, as a melanoma treatment.
Program released for annual business development forum
09 February, 2012 by AusBiotechAusBiotech has today launched the speaking program for the business development meeting of the year, to be held on the Gold Coast from 15-16 March.
Cochlear posts $20m loss on recall costs
08 February, 2012 by Dylan Bushell-EmblingCochlear (ASX:COH) has posted a $20.4 million net loss for the first half of this financial year, with earnings impacted by a major recall as well as forex losses.
Clinuvel files for marketing approval for SCENESSE in Europe
07 February, 2012 by Dylan Bushell-EmblingMelbourne-based Clinuvel (ASX:CUV) has applied for the right to market its SCENESSE subdermal treatment in the EU as a treatment for erythropoietic protoporphyria.
Alchemia making US inroads with coagulant
07 February, 2012 by Dylan Bushell-EmblingAlchemia Limited has revealed it is now selling more than $1.4 million per week worth of its lead drug, fondaparinux, in the US.
AusBiotech linked in to the industry network
07 February, 2012 by AusBiotechAusBiotech's two groups on social networking site LinkedIn have grown rapidly in the past year, this week reaching more than 1500 members (combined), cementing their place as the largest networks of their kind for Australian biotechnology and medical technology.
